Back to News
Market Impact: 0.2
Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Expands Supply Agreement with the University of Chieti-Pescara for PEX010 in the TEMPO Clinical Trial of Psilocybin for Treatment-Resistant Depression in Italy
Source: newsfilecorp.com
Healthcare & BiotechRegulation & Legislation
Filament expanded its supply agreement with Italy's University G. d'Annunzio of Chieti-Pescara after the TEMPO trial received authorization under the EU Clinical Trials Regulation. The expanded agreement will support enrollment of additional trial participants, representing incremental progress for the clinical program.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
More News
- OpenAI rogue agents leaked 53 images from ChatGPT users and reportedly created nearly 1 million links packing encoded bits of info
- Facebook found liable as TikTok settles for $100m over user safety
- What would a US diesel export ban mean for global fuel prices?
- Appeals court rules that states can regulate Kalshi’s sports prediction markets, dealing another legal blow to platforms
- US court rules against Kalshi, says states can regulate prediction markets
- Wall Street Week | China’s Trade Reckoning, Syracuse’s Second Chance, Humanoids in Healthcare
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- AI Tools for CFA Charterholders: An Evidence Standard
- Weekly Update: Unstructured Data Search, Ask AI, and Advanced Futures Data